Niraparib Shows Mixed Signals in Early Prostate Cancer Treatment

Niraparib Shows Mixed Signals in Early Prostate Cancer Treatment

(MedPage Today) -- At the recent American Urological Association annual meeting, data on niraparib (Zejula) in treatment-naive, DNA damage repair (DDR)-deficient localized prostate cancer offered new insights -- but also raised important questions...

Novel long noncoding RNA may serve as therapeutic target for prostate cancer

Northwestern Medicine investigators have discovered that a novel long noncoding RNA (lncRNA), which are usually 200 nucleotides longer than typical RNAs and are widely expressed in cells, could serve as a prognostic biomarker and therapeutic target for prostate cancer, according to a recent study published in Science Advances.

Immunotherapy for Prostate Cancer: What’s Now, What’s Next

While patients with advanced prostate cancer have many options to help manage the disease, more treatments are urgently needed. Harnessing a patient’s immune system to kill prostate cancer cells is one approach.  Learn about your immune system, the connection to prostate cancer, available treatments, and the future of this exciting field. PCF-funded Young Investigator Nicholas Zorko, MD, PhD of the University of Minnesota hosts a discussion with…

Pharma Pulse 5/23/25: The Role of AI in Solving Clinical Trial Diversity and Access Challenges; FDA Advisors Unanimously Snub Pfizer's Talzenna in Broader Prostate Cancer Population

Pharmaceutical Commerce connects biopharma executives to insights on business processes, technologies, and strategies for taking approved drugs to market.